ArticleJournal of cellular and molecular medicine2011
Differentiation and regeneration potential of mesenchymal progenitor cells derived from traumatized muscle tissue.
Article in Journal of cellular and molecular medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Preclinical validation of TGFβ inhibitors as a novel therapeutic strategy for post-traumatic heterotopic ossification.Scientific reports · 2025Article
- Stem Cells and Bone Tissue Engineering.Life (Basel, Switzerland) · 2024Review
- Adult Stem Cells for Cartilage Regeneration.Cureus · 2022Review
- Research trends of mesenchymal stem cells application in orthopedics: A bibliometric analysis of the past 2 decades.Frontiers in public health · 2022Article
- CD34 positive cells isolated from traumatized human skeletal muscle require the CD34 protein for multi-potential differentiation.Cellular signalling · 2020Article
- In vivo model of human post-traumatic heterotopic ossification demonstrates early fibroproliferative signature.Journal of translational medicine · 2019Article
- Article
- Tissue Engineering and Cell-Based Therapies for Fractures and Bone Defects.Frontiers in bioengineering and biotechnology · 2018Review
- Neurotrophic support by traumatized muscle-derived multipotent progenitor cells: Role of endothelial cells and Vascular Endothelial Growth Factor-A.Stem cell research & therapy · 2017Article
- Secreted trophic factors of mesenchymal stem cells support neurovascular and musculoskeletal therapies.Stem cell research & therapy · 2016Review
- Activation of non-myogenic mesenchymal stem cells during the disease progression in dystrophic dystrophin/utrophin knockout mice.Human molecular genetics · 2015Article
- A comparison of bone regeneration with human mesenchymal stem cells and muscle-derived stem cells and the critical role of BMP.Biomaterials · 2014Article
- Hip osteoarthritis in dogs: a randomized study using mesenchymal stem cells from adipose tissue and plasma rich in growth factors.International journal of molecular sciences · 2014Article
- Characterization of discrete subpopulations of progenitor cells in traumatic human extremity wounds.PloS one · 2014Article
- Mesenchymal progenitor cells derived from traumatized muscle enhance neurite growth.Journal of tissue engineering and regenerative medicine · 2013Article
- Role of stem/progenitor cells in reparative disorders.Fibrogenesis & tissue repair · 2012Article
- Cell sources for the regeneration of articular cartilage: the past, the horizon and the future.International journal of experimental pathology · 2012Review
- Inducible expression of neurotrophic factors by mesenchymal progenitor cells derived from traumatically injured human muscle.Molecular biotechnology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Mesenchymal stem cell (MSC) therapy is a promising approach to promote tissue regeneration by either differentiating the MSCs into the desired cell type or by using their trophic functions to promote endogenous tissue repair. These strategies of regenerative medicine are limited by the availability of MSCs at the point of clinical care. Our laboratory has recently identified multipotent mesenchymal progenitor cells (MPCs) in traumatically injured muscle tissue, and the objective of this study was to compare these cells to a typical population of bone marrow derived MSCs. Our hypothesis was that the MPCs exhibit multilineage differentiation and expression of trophic properties that make functionally them equivalent to bone marrow derived MSCs for tissue regeneration therapies. Quantitative evaluation of their proliferation, metabolic activity, expression of characteristic cell-surface markers and baseline gene expression profile demonstrate substantial similarity between the two cell types. The MPCs were capable of differentiation into osteoblasts, adipocytes and chondrocytes, but they appeared to demonstrate limited lineage commitment compared to the bone marrow derived MSCs. The MPCs also exhibited trophic (i.e. immunoregulatory and pro-angiogenic) properties that were comparable to those of MSCs. These results suggest that the traumatized muscle derived MPCs may not be a direct substitute for bone marrow derived MSCs. However, because of their availability and abundance, particularly following orthopaedic injuries when traumatized muscle is available to harvest autologous cells, MPCs are a promising cell source for regenerative medicine therapies designed to take advantage of their trophic properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.